| abstract |
This application relates to purinone compounds as kinase inhibitors. Disclosed herein are compounds that form a covalent bond with Bruton's tyrosine kinase (Btk). Irreversible inhibitors of Btk have also been described. Additionally, reversible inhibitors of Btk have also been described. Also disclosed are pharmaceutical compositions comprising the compound. Methods of using the Btk inhibitors, alone or in combination with other therapeutic agents, to treat autoimmune diseases or conditions, heteroimmune diseases or conditions, cancers including lymphoma, and inflammatory diseases or conditions are disclosed. |